中国麻风皮肤病杂志 ›› 2018, Vol. 34 ›› Issue (2): 125-128.

• 综述 • 上一篇    

特应性皮炎的免疫机制及Dupilumab治疗研究进展

郭远1，2 蔡羽恬1，2 郭宁宁1，2 李遇梅1，2   

  1. 1.江苏大学医学院，江苏 镇江?212001； 2.江苏大学附属医院皮肤科，江苏 镇江?212001
  • 出版日期:2018-02-15 发布日期:2018-12-06
  • 通讯作者: 李遇梅，E-mail:l.yumeili@ujs.edu.cn
  • 基金资助:
    2015年国家自然科学基金面上项目（编号：81573053）； 2015江苏省“333工程”培养资金资助项目（编号：BRA2015196） 镇江市第七批科技计划（编号：SS2015024

Immune mechanism and clinical research progress in the treatment of atopic dermatitis with dupilumab

GUO Yuan1，2, CAI Yutian 1，2, GUO Ningning1，2 , LI Yumei 1，2.   

  1. 1.Medical College of Jiangsu University，Zhenjiang 212001, China; 2.Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China
  • Online:2018-02-15 Published:2018-12-06
  • Contact: LI Yumei, E-mail: yumeili@ujs.edu.cn

PDF (PC)

163

摘要： Ⅱ型辅助性T细胞（Th2）在特应性皮炎（AD）皮损中显著增高，并促进IL-4和IL-13的分泌，通过共受体IL-4Rα介导下游信号转导。目前多种新型免疫抑制剂已在治疗AD的临床研究中，其中Dupilumab 是抗 IL-4 受体α亚基（IL-4Rα）的单克隆抗体，能竞争性抑制IL-4、IL-13与IL-4Rα结合并阻断其介导的下游信号转导，从而抑制皮肤慢性炎症的发生发展。 本文综述了特应性皮炎的免疫学发病机制及靶向生物制剂Dupilumab治疗的研究现状。

关键词: 特应性皮炎, 免疫机制, 生物制剂, Dupilumab

Abstract: The level of Th2 cells is increased in the lesions of atopic dermatitis (AD) and the Th2 cells can stimulate the secretion of IL-4 and IL-13. IL-4 and IL-13 can mediate the downstream signal transduction through the co-receptor IL-4Rα. A variety of new targeted immunosuppressive agents have been used in the clinical study of AD. Dupilumab is a monoclonal antibody to the anti-IL-4 receptor alpha subunit (IL-4Ralpha), which can inhibit IL-4 and IL-13 to bind to IL-4Ralpha and block its downstream signal transduction, resulting in the occurrence and control chronic inflammation. The update of the immunologic mechanism of dupilumab for treating AD is reviewed in this article.

Key words: atopic dermatitis, immune mechanism, biological agents, Dupilumab